Page last updated: 2024-09-05

sorafenib and Salivary Gland Neoplasms

sorafenib has been researched along with Salivary Gland Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R1
Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK1
Cho, NP; Cho, SD; Hong, IS; Jung, JY; Nam, JS; Shin, JA; Yu, HJ1
Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G1

Trials

2 trial(s) available for sorafenib and Salivary Gland Neoplasms

ArticleYear
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
    Head & neck, 2015, Volume: 37, Issue:2

    Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Salivary Gland Neoplasms; Sorafenib

2015
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 69

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult

2016

Other Studies

2 other study(ies) available for sorafenib and Salivary Gland Neoplasms

ArticleYear
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Acta clinica Belgica, 2020, Volume: 75, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib

2020
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
    Head & neck, 2015, Volume: 37, Issue:9

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Heterografts; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Salivary Gland Neoplasms; Sensitivity and Specificity; Signal Transduction; Sorafenib; Tumor Cells, Cultured

2015